RxDoctor Payments Data

Allison Liddell, MD

Infectious Disease · Dallas, TXNPI 1831174069

Payments from drug & device makers

$10,349in general payments, 2019–2025

Across 529 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$3K
  • Merck$1K
  • Johnson & Johnson$1K
  • AbbVie$714
  • Gilead$674
  • Paratek Pharmaceuticals, Inc.$637
  • plus $4K from 16 others

What the payments were for

  • Food & beverage$10,11698%
  • Education$2342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,349 in reported general payments places this provider in the 80th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$89,270
Medicare patients
244
Services billed
1,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala38$165,926
JulucaDolutegravir/Rilpivirine23$80,489
OdefseyEmtricitab/Rilpiviri/Tenof Ala20$71,186
TriumeqAbacavir/Dolutegravir/Lamivudi15$62,515
StribildElviteg/Cob/Emtri/Tenofo Disop12$58,003
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$43,089
PrezcobixDarunavir/Cobicistat13$37,144
ErtapenemErtapenem Sodium12$4,235
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam16$2,056
MicafunginMicafungin Sodium13$1,990
Cefepime Hcl16$1,932
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df12$965
Cefazolin Sodium19$684
Doxycycline Hyclate22$606
Doxycycline Monohydrate24$579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Stribild, Genvoya$674$267,01961 claims
Viiv Healthcare CompanyJuluca, Triumeq$2,668$143,00438 claims
Johnson & JohnsonPrezcobix$1,029$37,14413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 576 infectious disease providers in Texas.

Other infectious disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →